Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

Total article views   HTML views PDF downloads Totals
9,347 Dovepress* 8,466+ 1,148 9,614
PubMed Central* 881 230 1,111
Totals 9,347 1,378 10,725
*Since 8 November 2019
Total mentioned Facebook Delicious Reddit Twitter Others
6 0 0 0 2 4

View citations on PubMed Central and Google Scholar